OS Therapies Reports Positive Survival Data from Phase 2b OST-HER2 Osteosarcoma Trial

Reuters10-22

<a href="https://laohu8.com/S/OSTX">OS Therapies</a> Reports Positive Survival Data from Phase 2b OST-HER2 Osteosarcoma Trial

OS Therapies Inc. has announced additional overall and event free survival data from its 41-patient Phase 2b clinical trial of OST-HER2, an off-the-shelf immunotherapeutic candidate for recurrent, fully resected, pulmonary metastatic osteosarcoma. The company previously presented statistically significant positive final 2-year overall survival data from this trial on October 10, 2025. Subgroup analyses were performed following participation in an FDA/Osteosarcoma Institute workshop. The 1-year event free survival was reported as 28.6% among evaluable patients. OS Therapies plans to meet with regulatory agencies, including the FDA, MHRA, and EMA, to review the survival data and discuss plans to file for Biologics License Authorization under the FDA's Accelerated Approval Program and for conditional approvals in the UK and EU.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 271441) on October 22, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2577367291?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-22 21:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577367291","market":"us","top_or_hot":-1,"title":"OS Therapies Reports Positive Survival Data from Phase 2b OST-HER2 Osteosarcoma Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OSTX\">OS Therapies</a> Reports Positive Survival Data from Phase 2b OST-HER2 Osteosarcoma Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        OS Therapies Inc. has announced additional overall and event free survival data from its 41-patient Phase 2b clinical trial of OST-HER2, an off-the-shelf immunotherapeutic candidate for recurrent, fully resected, pulmonary metastatic osteosarcoma. The company previously presented statistically significant positive final 2-year overall survival data from this trial on October 10, 2025. Subgroup analyses were performed following participation in an FDA/Osteosarcoma Institute workshop. The 1-year event free survival was reported as 28.6% among evaluable patients. OS Therapies plans to meet with regulatory agencies, including the FDA, MHRA, and EMA, to review the survival data and discuss plans to file for Biologics License Authorization under the FDA's Accelerated Approval Program and for conditional approvals in the UK and EU.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 271441) on October 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OS Therapies Reports Positive Survival Data from Phase 2b OST-HER2 Osteosarcoma Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOS Therapies Reports Positive Survival Data from Phase 2b OST-HER2 Osteosarcoma Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-22 21:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OSTX\">OS Therapies</a> Reports Positive Survival Data from Phase 2b OST-HER2 Osteosarcoma Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        OS Therapies Inc. has announced additional overall and event free survival data from its 41-patient Phase 2b clinical trial of OST-HER2, an off-the-shelf immunotherapeutic candidate for recurrent, fully resected, pulmonary metastatic osteosarcoma. The company previously presented statistically significant positive final 2-year overall survival data from this trial on October 10, 2025. Subgroup analyses were performed following participation in an FDA/Osteosarcoma Institute workshop. The 1-year event free survival was reported as 28.6% among evaluable patients. OS Therapies plans to meet with regulatory agencies, including the FDA, MHRA, and EMA, to review the survival data and discuss plans to file for Biologics License Authorization under the FDA's Accelerated Approval Program and for conditional approvals in the UK and EU.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 271441) on October 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OSTX","symbol_name":"OS Therapies","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDL472r3y:1","article_id":"2577367291","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577367291","pubTimestamp":1761138969,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"OS Therapies Inc. has announced additional overall and event free survival data from its 41-patient Phase 2b clinical trial of OST-HER2, an off-the-shelf immunotherapeutic candidate for recurrent, fully resected, pulmonary metastatic osteosarcoma. The company previously presented statistically significant positive final 2-year overall survival data from this trial on October 10, 2025. Subgroup analyses were performed following participation in an FDA/Osteosarcoma Institute workshop. The 1-year event free survival was reported as 28.6% among evaluable patients. OS Therapies plans to meet with regulatory agencies, including the FDA, MHRA, and EMA, to review the survival data and discuss plans to file for Biologics License Authorization under the FDA's Accelerated Approval Program and for conditional approvals in the UK and EU.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OSTX":"OS Therapies","BK4139":"生物科技"},"translate_title":"OS Therapies报告2b期OST-HER2骨肉瘤试验的阳性生存数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OSTX":0.9},"content_text":"OS Therapies Reports Positive Survival Data from Phase 2b OST-HER2 Osteosarcoma Trial\n    \n\n        OS Therapies Inc. has announced additional overall and event free survival data from its 41-patient Phase 2b clinical trial of OST-HER2, an off-the-shelf immunotherapeutic candidate for recurrent, fully resected, pulmonary metastatic osteosarcoma. The company previously presented statistically significant positive final 2-year overall survival data from this trial on October 10, 2025. Subgroup analyses were performed following participation in an FDA/Osteosarcoma Institute workshop. The 1-year event free survival was reported as 28.6% among evaluable patients. OS Therapies plans to meet with regulatory agencies, including the FDA, MHRA, and EMA, to review the survival data and discuss plans to file for Biologics License Authorization under the FDA's Accelerated Approval Program and for conditional approvals in the UK and EU.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 271441) on October 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2577367291","isCrawlerRequest":true}